#3091 A STUDY FOR HOSPITALIZED PATIENTS WITH COVID-19 WITH/WITHOUT IMMUNOSUPPRESSION AND RENAL FAILURE: DOES THE SURVIVAL RATE CHANGE?

Abstract

Abstract Background and Aims Introduction The purpose of our research topic was to study the survival of immunocompromised or non-immunosuppressed patients as well as patients with Chronic Kidney Disease who were hospitalized due to covid-19 infection during a two-year period (2020-2022). Method Material and Methods A total of 1270 patients (of whom 570 were women) with a mean age of 63 years (+/- 24 years) were studied. From these, 1000 patients were without immunosuppression and 270 were theoretically and practically immunosuppressed, including 30 patients with Chronic Kidney Disease and of these 10 were with end-stage Chronic Kidney Disease. It is important to mention that 87 patients had to be hospitalized in the ICU, of which 74 died. The rest were hospitalized in the Biocontainment Unit, where 92 deaths were observed. 100 patients without immunosuppression died and 66 with immunosuppression. From the patients with End-Stage Chronic Kidney Disease, 3 died, theoretically falling into the immunocompromised category. The treatment protocol included all the therapeutic measures recommended by CCD. Results There was no statistically significant difference betweem the rate of death in immunocompromised patients and those who belonged in non immunocompromised group. However, there was a simple difference in deaths (66 out of 270 immunosuppresed patients) and 100 in non-immunocompromised patients, while there was also a difference in their need for hospitalization in the ICU and the Unit for Special Infections, but not statistically significant. Conclusion In conclusion, it appears that the immunocompromised are more prone to severe diseases having poor outcome. Furthermore, it was observed that patients with End Stage Chronic Kidney Disease had a fairly low mortality rate even though they are considered immunocompromised.